Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05700721
Title	Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	Yes
Sponsors	M.D. Anderson Cancer Center
Indications	lung small cell carcinoma triple-receptor negative breast cancer lung non-small cell carcinoma Advanced Solid Tumor
Therapies	Dostarlimab-gxly + Niraparib
Age Groups:	adult \| senior
Covered Countries	USA